<?xml version="1.0" encoding="utf-8"?><?xml-stylesheet type='text/xsl' href='/uploadedfiles/transforms/rsspretty.xsl'?><rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0"><channel><title>Pew Health Expert: Kathleen Stratton</title><link>http://www.pewhealth.org/</link><description>Stratton is Director, Innovate FDA, which seeks transparency in physician-industry relationships and reduction of conflicts of interest affecting patient care.</description><item><guid isPermaLink="false">85899431927</guid><link>http://www.pewhealth.org/news-room/media-coverage/report-says-fda-needs-workforce-improvements-85899431927</link><title>''Report Says FDA Needs Workforce Improvements''</title><description>&lt;p&gt;In 2007, an agency panel found that the FDA’s "scientific workforce does not have sufficient capacity and capability" and the agency is "not positioned to meet current or emerging regulatory responsibilities." The Pew Charitable Trusts wanted to know if that’s still the case, and asked the Partnership for Public Service to find out. "FDA has made progress," says the Partnership’s report, but the agency "continues to have significant workforce and management challenges in the scientific and medical arenas that need to be addressed."&lt;/p&gt;</description><a10:updated>2012-11-21T13:00:36-05:00</a10:updated></item><item><guid isPermaLink="false">85899420402</guid><link>http://www.pewhealth.org/news-room/video-library/expert-profile-kathleen-stratton-85899420402</link><title>Expert Profile: Kathleen Stratton</title><description>&lt;p&gt;Kathleen Stratton, &lt;strong&gt;Project Director, Innovate FDA&lt;/strong&gt; &lt;/p&gt;</description><a10:updated>2012-09-28T17:25:37-04:00</a10:updated></item><item><guid isPermaLink="false">85899389291</guid><link>http://www.pewhealth.org/news-room/media-coverage/study-fda-reviews-new-drugs-faster-than-europe-canada-85899389291</link><title>''Study: FDA reviews new drugs faster than Europe, Canada''</title><description>&lt;p&gt;"Researchers say the U.S. approved more new medicines in less time than Europe and Canada in the last decade, challenging long-standing criticisms that the Food and Drug Administration lags behind its peers in clearing important new drugs."&lt;/p&gt;</description><a10:updated>2012-05-17T11:25:00-04:00</a10:updated></item></channel></rss>